These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20880883)

  • 1. Optimal antiviral treatment strategies and the effects of resistance.
    Hansen E; Day T
    Proc Biol Sci; 2011 Apr; 278(1708):1082-9. PubMed ID: 20880883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
    Handel A; Longini IM; Antia R
    J Theor Biol; 2009 Jan; 256(1):117-25. PubMed ID: 18952105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.
    Arino J; Bowman CS; Moghadas SM
    BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral resistance and the control of pandemic influenza.
    Lipsitch M; Cohen T; Murray M; Levin BR
    PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.
    McCaw JM; Wood JG; McCaw CT; McVernon J
    PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
    Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
    PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimality of a time-dependent treatment profile during an epidemic.
    Jaberi-Douraki M; Moghadas SM
    J Biol Dyn; 2013; 7(1):133-47. PubMed ID: 23859002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the effects of drug resistant influenza virus in a pandemic.
    Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
    Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-wide emergence of antiviral resistance during pandemic influenza.
    Moghadas SM; Bowman CS; Röst G; Wu J
    PLoS One; 2008 Mar; 3(3):e1839. PubMed ID: 18350174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance.
    Alexander ME; Dietrich SM; Hua Y; Moghadas SM
    J Theor Biol; 2009 Jul; 259(2):253-63. PubMed ID: 19344730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter to the editor: Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season.
    Ciancio BC; Nicoll A
    Euro Surveill; 2007 Jun; 12(6):E070628.4; author reply E070628.5. PubMed ID: 17868571
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimal control for pandemic influenza: the role of limited antiviral treatment and isolation.
    Lee S; Chowell G; Castillo-Chávez C
    J Theor Biol; 2010 Jul; 265(2):136-50. PubMed ID: 20382168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of drug-resistant influenza virus: population dynamical considerations.
    Regoes RR; Bonhoeffer S
    Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence and transmission of amantadine-resistant influenza A in a nursing home.
    Schilling M; Gravenstein S; Drinka P; Cox N; Krause P; Povinelli L; Shult P
    J Am Geriatr Soc; 2004 Dec; 52(12):2069-73. PubMed ID: 15571544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis or treatment? Optimal use of an antiviral stockpile during an influenza pandemic.
    McCaw JM; McVernon J
    Math Biosci; 2007 Oct; 209(2):336-60. PubMed ID: 17416393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal control and sensitivity analysis of an influenza model with treatment and vaccination.
    Tchuenche JM; Khamis SA; Agusto FB; Mpeshe SC
    Acta Biotheor; 2011 Mar; 59(1):1-28. PubMed ID: 20140696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool.
    Adalja A; Inglesby T
    Expert Rev Anti Infect Ther; 2019 Jul; 17(7):467-470. PubMed ID: 31216912
    [No Abstract]   [Full Text] [Related]  

  • 18. A hospital-based strategy for setting priorities for antiviral prophylaxis during an influenza pandemic.
    Hsu EB; Millin MG
    Biosecur Bioterror; 2008 Jun; 6(2):171-8. PubMed ID: 18563994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with oseltamivir in the control of a nursing home influenza B outbreak.
    Parker R; Loewen N; Skowronski D
    Can Commun Dis Rep; 2001 Mar; 27(5):37-40. PubMed ID: 11260987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can treatment increase the epidemic size?
    Xiao Y; Brauer F; Moghadas SM
    J Math Biol; 2016 Jan; 72(1-2):343-61. PubMed ID: 25925242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.